Christopher Haqq

2022 - Elicio Therapeutics

In 2022, Christopher Haqq earned a total compensation of $1.2M as Executive Vice President, Head of Research and Development and Chief Medical Officer at Elicio Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$186,010
Option Awards$511,321
Salary$465,025
Total$1,162,356

Haqq received $511.3K in option awards, accounting for 44% of the total pay in 2022.

Haqq also received $186K in non-equity incentive plan and $465K in salary.

Rankings

In 2022, Christopher Haqq's compensation ranked 2,745th out of 5,736 executives tracked by ExecPay. In other words, Haqq earned more than 52.1% of executives.

ClassificationRankingPercentile
All
2,745
out of 5,736
52nd
Division
Manufacturing
1,527
out of 3,125
51st
Major group
Chemicals And Allied Products
706
out of 1,416
50th
Industry group
Drugs
658
out of 1,317
50th
Industry
Pharmaceutical Preparations
475
out of 963
51st
Source: SEC filing on September 27, 2024.

Haqq's colleagues

We found three more compensation records of executives who worked with Christopher Haqq at Elicio Therapeutics in 2022.

2022

Jay Venkatesan

Elicio Therapeutics

Chief Executive Officer

2022

Robert Connelly

Elicio Therapeutics

Chief Executive Officer

2022

Jennifer Rhodes

Elicio Therapeutics

General Counsel

News

You may also like